Please assess the completion status of the following clinical trial:

Trial Title: Assessment of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 Peptide Antigens

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Male or female subjects aged 18 - 65 years of age, inclusive, in good general health as determined by medical evaluation Subject receives a negativeSARS-CoV-2 PCR test result at their screening or baseline visit~Exclusion Criteria:~Subjects will be excluded if they have clinically significant underlying conditions associated with high risk for severe COVID-19 infections as identified by the Centers for Disease Control and Prevention (CDC) (Appendix 2). These conditions include, but are not limited to: chronic obstructive pulmonary disease, diabetes mellitus (Type 1 and 2), obesity, hypertension, heart disease, and cerebrovascular disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): Healthy uninfected/unexposed subjects to SARS-CoV-2
- Cohort 2 (Type: ACTIVE_COMPARATOR): Subjects who have recovered from SARS-CoV-2 infection
- Cohort 3 (Type: SHAM_COMPARATOR): Subjects who have received a complete SARS-CoV-2 vaccine course

Based on this trial design, predict the completion outcome and termination type (if applicable).